07:19 AM EDT, 07/25/2024 (MT Newswires) -- West Pharmaceutical (WST) reported Q2 adjusted earnings of $1.52 per diluted share on Thursday, down from $2.11 a year earlier.

Analysts polled by Capital IQ expected $1.73.

Revenue for the quarter ended June 30 was $702.1 million, compared with $753.8 million a year earlier.

Analysts surveyed by Capital IQ expected $728.7 million.

The company slashed its outlook for FY24 adjusted diluted earnings to $6.35 to $6.65 per share from $7.63 to $7.88 previously. Analysts surveyed by Capital IQ expect $7.73.

West also trimmed its 2024 revenue guidance to $2.87 billion to $2.90 billion from the prior range of $3 billion to $3.03 billion. Analysts polled by Capital IQ expect $3.01 billion.

West Pharmaceutical shares fell by more than 16% in premarket trading.

Price: 284.00, Change: -39.77, Percent Change: -12.28